NASDAQ:ELYM Eliem Therapeutics (ELYM) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free ELYM Stock Alerts $2.79 +0.03 (+1.09%) (As of 02:14 PM ET) Add Compare Share Share Today's Range$2.72▼$2.8050-Day Range$2.54▼$2.9752-Week Range$2.34▼$3.72Volume2,377 shsAverage Volume5,903 shsMarket Capitalization$76.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Eliem Therapeutics alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Eliem Therapeutics Stock (NASDAQ:ELYM)Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.Read More ELYM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELYM Stock News HeadlinesMarch 6, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn SituationNovember 19, 2023 | morningstar.comCheckpoint Therapeutics Inc CKPTMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… November 15, 2023 | morningstar.comEliem Therapeutics Inc ELYMSeptember 28, 2023 | finance.yahoo.comEliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJuly 21, 2023 | finance.yahoo.comEliem (ELYM) to Explore Strategic Options, Stock Rises 6%July 21, 2023 | msn.comEliem Therapeutics’ stock soars 21% premarket after company says it may sell itselfJuly 20, 2023 | benzinga.comWhat's Happening With Eliem Therapeutics Shares Today?March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… July 20, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic AlternativesJuly 20, 2023 | marketwatch.comEliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYMJuly 20, 2023 | markets.businessinsider.comWhy Is Eliem Therapeutics (ELYM) Stock Up 6% Today?July 20, 2023 | finance.yahoo.comEliem Therapeutics Announces Plans to Explore Strategic AlternativesJune 7, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)May 25, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)May 12, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business HighlightsMay 11, 2023 | seekingalpha.comEliem Therapeutics GAAP EPS of -$0.84May 11, 2023 | finance.yahoo.comEliem Therapeutics Reports First Quarter Financial Results and Business HighlightsApril 21, 2023 | finance.yahoo.comWe're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash WiselyMarch 9, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)March 7, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsMarch 6, 2023 | finance.yahoo.comEliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsFebruary 23, 2023 | seekingalpha.comELYM Eliem Therapeutics, Inc.February 23, 2023 | finance.yahoo.comEliem Therapeutics slashing staff amid leadership shakeupFebruary 18, 2023 | finance.yahoo.comEliem Pauses Development On Depression Drug, Lays Off 55% WorkforceFebruary 10, 2023 | msn.comEliem Therapeutics down after announcing reprioritization plans, layoffsFebruary 9, 2023 | finance.yahoo.comEliem Therapeutics Provides Strategic Update and Announces Leadership TransitionSee More Headlines Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/28/2024Next Earnings (Estimated)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.55% Return on Assets-32.29% Debt Debt-to-Equity RatioN/A Current Ratio38.76 Quick Ratio38.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.84 per share Price / Book0.57Miscellaneous Outstanding Shares27,570,000Free Float26,277,000Market Cap$76.09 million OptionableNot Optionable Beta0.50 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Andrew Levin M.D. (Age 46)Ph.D., Principal Financial Officer & Executive Chairman Comp: $73kDr. Valerie Morisset Ph.D. (Age 54)Chief Scientific Officer and Executive VP of Research & Development Comp: $617.87kMs. Emily Pimblett (Age 40)Principal Accounting Officer Ms. Jo Palmer-Phillips Ph.D.Chief Development OfficerKey CompetitorsBioLineRxNASDAQ:BLRXOncolytics BiotechNASDAQ:ONCYEnlivex TherapeuticsNASDAQ:ENLVConnect BiopharmaNASDAQ:CNTBAssembly BiosciencesNASDAQ:ASMBView All CompetitorsInstitutional OwnershipNorthern Trust CorpBought 37,530 shares on 2/13/2024Ownership: 0.177%BML Capital Management LLCBought 241,737 shares on 1/30/2024Ownership: 7.907%Cerity Partners LLCBought 13,821 shares on 1/26/2024Ownership: 0.050%View All Institutional Transactions ELYM Stock Analysis - Frequently Asked Questions How have ELYM shares performed in 2024? Eliem Therapeutics' stock was trading at $2.70 at the beginning of 2024. Since then, ELYM stock has increased by 3.3% and is now trading at $2.79. View the best growth stocks for 2024 here. Are investors shorting Eliem Therapeutics? Eliem Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 13,000 shares, an increase of 19.3% from the February 29th total of 10,900 shares. Based on an average daily volume of 6,800 shares, the days-to-cover ratio is currently 1.9 days. Approximately 0.1% of the company's stock are sold short. View Eliem Therapeutics' Short Interest. When is Eliem Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our ELYM earnings forecast. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.19. When did Eliem Therapeutics IPO? Eliem Therapeutics (ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO. Who are Eliem Therapeutics' major shareholders? Eliem Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BML Capital Management LLC (7.91%), Northern Trust Corp (0.18%) and Cerity Partners LLC (0.05%). How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELYM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.